1. Al-Momani E, Zlatopolskiy BD, Machulla HJ, Reske SN, Solbach C. Radiosynthesis of carbon-11 labeled 6-methyldopamine ([(1)(1)C]MeDA). Appl Radiat Isot 2012; 70:1475-1479.
  2. Al-Momani E, Zlatopolskiy BD, Solbach C, Machulla HJ, Reske SN. Synthesis of no-carrier-added 6- C-11 methyl-L-DOPA. Journal of Radioanalytical and Nuclear Chemistry 2012; 293:573-577.
  3. Awad ED, El-Abadelah MM, Matar S, Zihlif MA, Naffa RG, Al-Momani EQ, Mubarak MS. Synthesis and Biological Activity of Some 3-(4-(Substituted)-piperazin-1-yl)cinnolines. Molecules 2012; 17:227-239.
  4. Burstel I, Siebert E, Winter G, Hummel P, Zebger I, Friedrich B, Lenz O. A universal scaffold for synthesis of the Fe(CN)2(CO) moiety of [NiFe] hydrogenase. J Biol Chem 2012; 287:38845-38853.
  5. Fortuin AS, Deserno WM, Meijer HJ, Jager GJ, Takahashi S, Debats OA, Reske SN, Schick C, Krause BJ, van Oort I, Witjes AJ, Hoogeveen YL, van Lin EN, Barentsz JO. Value of PET/CT and MR lymphography in treatment of prostate cancer patients with lymph node metastases. Int J Radiat Oncol Biol Phys 2012; 84:712-718.
  6. Jilg CA, Rischke HC, Reske SN, Henne K, Grosu AL, Weber W, Drendel V, Schwardt M, Jandausch A, Schultze-Seemann W. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol 2012; 188:2190-2197.
  7. Kletting P, Muller B, Erentok B, Schmaljohann J, Behrendt FF, Reske SN, Mottaghy FM, Glatting G. Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy. Med Phys 2012; 39:5708-5717.
  8. Kletting P, Muller B, Schmaljohann J, Behrendt FF, Reske SN, Mottaghy FM, Glatting G. Differences in pretherapeutic and therapeutic biodistributions in peptide receptor radionuclide therapy (PRRT). European Journal of Nuclear Medicine and Molecular Imaging 2012; 39:S351-S351.
  9. Kotzerke J, Luster M, Freesmeyer M. [Give me a fixed point in space, and I will lift the world upside down]. Nuklearmedizin 2012; 51:65-66.
  10. Luster M, Hanscheid H, Freudenberg LS, Verburg FA. Radioiodine therapy of metastatic lesions of differentiated thyroid cancer. J Endocrinol Invest 2012; 35:21-29.
  11. Malik N, Lin X, Loffler D, Shen B, Solbach C, Reischl G, Voelter W, Machulla HJ. Synthesis of O- 2- F-18 fluoro-3-(2-nitro-1H-imidazole-1-yl)propyl tyrosine ( F-18 FNT ) as a new class of tracer for imaging hypoxia. Journal of Radioanalytical and Nuclear Chemistry 2012; 292:1025-1033.
  12. Malik N, Zlatopolskiy B, Machulla HJ, Reske SN, Solbach C. One pot radiofluorination of a new potential PSMA ligand Al18F NOTA-DUPA-Pep. Journal of Labelled Compounds & Radiopharmaceuticals 2012; 55:320-325.
  13. Pauls S, Schmidt SA, Juchems MS, Klass O, Luster M, Reske SN, Brambs HJ, Feuerlein S. Diffusion-weighted MR imaging in comparison to integrated [(18)F]-FDG PET/CT for N-staging in patients with lung cancer. Eur J Radiol 2012; 81:178-182.
  14. Reiners C, Luster M. Radiotherapy: Radioiodine in thyroid cancer-how to minimize side effects. Nat Rev Clin Oncol 2012; 9:432-434.
  15. Reiners C, Lassmann M, Luster M. Recombinant human thyrotropin: safety and quality of life evaluation. J Endocrinol Invest 2012; 35:30-35.
  16. Reske SN, Moritz S, Kull T. [11C]Choline-PET/CT for outcome prediction of salvage radiotherapy of local relapsing prostate carcinoma. Q J Nucl Med Mol Imaging 2012; 56:430-439.
  17. Straub S, Feneberg E, Kassubek J, Pinkhardt E, von Arnim C, Kornhuber J, Schneider A, Jahn H, Danek A, Diehl-Schmid J, Drzezga A, Foerstl H, Lauer M, Prudlo J, Luster M, Ludolph AC, Schroeter M, Uttner I, Otto M. Evaluation of Visual Rating Scales for MRI Supported Diagnosis of Frontotemporal Lobar Degeneration. Dementia and Geriatric Cognitive Disorders 2012; 33:253-253.
  18. Verburg FA, Dietlein M, Freudenberg L, Leboulleux S, Pitoia F, Reiners C, Stokkel M, Luster M. Recombinant human TSH versus thyroid hormone withdrawal. J Nucl Med 2012; 53:1815-1816; author reply 1816-1817.
  19. Weber T, Ohlhauser D, Hillenbrand A, Henne-Bruns D, Reske SN, Luster M. Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma. Horm Metab Res 2012; 44:904-908.